Lineage Cell Therapeutics, Inc. (LCTX): Price and Financial Metrics
LCTX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LCTX is 0.02 -- better than only 9.23% of US stocks.
- LCTX's price/sales ratio is 228.38; that's higher than the P/S ratio of 97.68% of US stocks.
- Revenue growth over the past 12 months for Lineage Cell Therapeutics Inc comes in at -48.05%, a number that bests only 6.55% of the US stocks we're tracking.
- Stocks that are quantitatively similar to LCTX, based on their financial statements, market capitalization, and price volatility, are INSM, MDWD, ALKS, JNPR, and ATNX.
- LCTX's SEC filings can be seen here. And to visit Lineage Cell Therapeutics Inc's official web site, go to www.lineagecell.com.
LCTX Stock Price Chart Interactive Chart >
LCTX Price/Volume Stats
| Current price | $2.58 | 52-week high | $3.13 |
| Prev. close | $2.53 | 52-week low | $0.70 |
| Day low | $2.46 | Volume | 689,000 |
| Day high | $2.65 | Avg. volume | 1,874,804 |
| 50-day MA | $2.45 | Dividend yield | N/A |
| 200-day MA | $1.56 | Market Cap | 417.03M |
Lineage Cell Therapeutics, Inc. (LCTX) Company Bio
Lineage Cell Therapeutics, Inc. operates as a biotechnology company. The Company offers cell-based therapies and gene marker-based molecular diagnostics for diseases and degenerative conditions. Lineage Cell Therapeutics serves patients in the United States.
Latest LCTX News From Around the Web
Below are the latest news stories about Lineage Cell Therapeutics Inc that investors may wish to consider to help them evaluate LCTX as an investment opportunity.
Lineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate UseUnder a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's (NYSE: LCTX) OpRegen has been used to treat a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) at Hadassah-Hebrew University Medical Center in Jerusalem. The patient was presented with sudden and severe visual acuity decreases in one eye. BCVA in the worse vision eye was measured at 20/200, compared to 20/40 in the patient's contralateral eye. The delivery of OpRegen retinal pigment epithelium (RPE) cells via pars plana vitrectomy was successful, with no complications arising during the procedure, and the patient remains in follow-up. AVMD is a retinal disease characterized by round, yellowish deposits found beneath the central retina or macula respo... |
Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate UseLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced that a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) had recently been treated with its lead product candidate, OpRegen, at Hadassah-Hebrew University Medical Center in Jerusalem, using a named patient compassionate use approval granted by the Israeli Ministry of Health. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space and is currently being investigated in a 24-patient phase 1/2a clinical trial for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). |
Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic AtrophyLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Additional interim data were collected on all 24 patients enrolled in the study, including the 12 patients treated in Cohort 4, which feature less advanced disease, better baseline visual acuity, and smaller areas of GA. |
Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Benzinga Global Biotech Small Cap conference on March 24, 2021 at 11:50am Eastern Time / 8:50am Pacific Time. Mr. Culley will also be participating in a panel entitled "Coming Together to Address Unmet Medical Needs," on March 24, 2021 at 12:50pm Eastern Time / 9:50am Pacific Time. |
Lineage Cell Therapeutics' (LCTX) CEO Brian Culley on Q4 2020 Results - Earnings Call TranscriptLineage Cell Therapeutics, Inc. (LCTX) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants Ioana Hone – Director-Investor Relations Brian Culley – Chief Executive Officer Brandi Roberts – Chief Financial Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Jason McCarthy – Maxim Group Keay Nakae... |
LCTX Price Returns
| 1-mo | 4.03% |
| 3-mo | 24.04% |
| 6-mo | 88.32% |
| 1-year | N/A |
| 3-year | 3.61% |
| 5-year | -15.41% |
| YTD | 46.59% |
| 2020 | 97.75% |
| 2019 | -2.20% |
| 2018 | -57.67% |
| 2017 | -40.44% |
| 2016 | -11.95% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...